Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-
Sezary Syndrome
Vanderbilt University Medical CenterSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Sezary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
Prednisone Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
(+)-Vincristine Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
Cyclosporin A Ohio State University Comprehensive Cancer Center | Phase 2 | BB |
Denileukin Diftitox Eisai Inc. | Phase 4 | B |
View all 40 →
Same molecule, other indications
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →